ACHFF OTC Stock Today

ACHFF
 Stock
  

USD 2.34  0.15  6.85%   

Market Performance
0 of 100
Odds Of Distress
Less than 26
Arch Biopartners is trading at 2.34 as of the 2nd of July 2022, a 6.85 percent increase since the beginning of the trading day. The stock's lowest day price was 2.34. Arch Biopartners has about a 26 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Arch Biopartners are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of July 2020 and ending today, the 2nd of July 2022. Click here to learn more.
Fiscal Year End
September
Category
Healthcare
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company has 62.29 M outstanding shares. More on Arch Biopartners

Moving together with Arch Biopartners

0.84DISWalt Disney Fiscal Year End 9th of November 2022 PairCorr
0.74MSFTMicrosoft Corp Fiscal Year End 26th of July 2022 PairCorr

Moving against Arch Biopartners

0.76TATT Inc Earnings Call  In Two WeeksPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Arch Biopartners OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Arch Biopartners' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arch Biopartners or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Arch Biopartners generated a negative expected return over the last 90 days
The company has accumulated 4.36 M in total debt. Arch Biopartners has a current ratio of 0.77, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ACHFF to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity.
Arch Biopartners has accumulated about 734 K in cash with (879.86 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Roughly 19.0% of the company shares are held by company insiders
President CEO, DirectorRichard Muruve
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Arch Biopartners' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedUndervalued
Arch Biopartners [ACHFF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Small-Cap' category with current market capitalization of 146.2 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arch Biopartners's market, we take the total number of its shares issued and multiply it by Arch Biopartners's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Arch Biopartners classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 62.29 M outstanding shares. Arch Biopartners has accumulated about 734 K in cash with (879.86 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Arch Biopartners Probability Of Bankruptcy
Ownership
Arch Biopartners holds a total of sixty-two million two hundred ninety thousand outstanding shares. Arch Biopartners shows 19.19 percent if its outstanding shares held by insiders and 19.19 percent owned by other corporate entities . Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check ACHFF Ownership Details

ACHFF Stock Price Odds Analysis

What are Arch Biopartners' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Arch Biopartners jumping above the current price in 90 days from now is about 84.13%. The Arch Biopartners probability density function shows the probability of Arch Biopartners otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Arch Biopartners has a beta of -0.2347. This suggests as returns on benchmark increase, returns on holding Arch Biopartners are expected to decrease at a much lower rate. During the bear market, however, Arch Biopartners is likely to outperform the market. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Arch Biopartners is significantly underperforming DOW.
  Odds Below 2.34HorizonTargetOdds Above 2.34
15.80%90 days
 2.34 
84.13%
Based on a normal probability distribution, the odds of Arch Biopartners to move above the current price in 90 days from now is about 84.13 (This Arch Biopartners probability density function shows the probability of ACHFF OTC Stock to fall within a particular range of prices over 90 days) .

Arch Biopartners Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Arch Biopartners market risk premium is the additional return an investor will receive from holding Arch Biopartners long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Arch Biopartners. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Arch Biopartners' alpha and beta are two of the key measurements used to evaluate Arch Biopartners' performance over the market, the standard measures of volatility play an important role as well.

ACHFF Stock Against Markets

Picking the right benchmark for Arch Biopartners otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arch Biopartners otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arch Biopartners is critical whether you are bullish or bearish towards Arch Biopartners at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Arch Biopartners without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Arch Biopartners Corporate Directors

Arch Biopartners corporate directors refer to members of an Arch Biopartners board of directors. The board of directors generally takes responsibility for the Arch Biopartners' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Arch Biopartners' board members must vote for the resolution. The Arch Biopartners board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Conor Gunne - Independent DirectorProfile
Richard Rossman - DirectorProfile
Andrew Bishop - DirectorProfile
Claude Allary - Independent DirectorProfile

Investing Arch Biopartners

You need to understand the risk of investing before taking a position in Arch Biopartners. The danger of trading Arch Biopartners is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arch Biopartners is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arch Biopartners. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arch Biopartners is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Arch Biopartners information on this page should be used as a complementary analysis to other Arch Biopartners' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for ACHFF OTC Stock analysis

When running Arch Biopartners price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Is Arch Biopartners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arch Biopartners. If investors know ACHFF will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arch Biopartners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
146.2 M
Quarterly Revenue Growth YOY
52.28
Return On Assets
0.65
The market value of Arch Biopartners is measured differently than its book value, which is the value of ACHFF that is recorded on the company's balance sheet. Investors also form their own opinion of Arch Biopartners' value that differs from its market value or its book value, called intrinsic value, which is Arch Biopartners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arch Biopartners' market value can be influenced by many factors that don't directly affect Arch Biopartners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arch Biopartners' value and its price as these two are different measures arrived at by different means. Investors typically determine Arch Biopartners value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arch Biopartners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.